Open access peer-reviewed chapter

Introductory Chapter: Muscular Dystrophy and Recent Therapeutic Strategy

By Kunihiro Sakuma

Submitted: March 14th 2019Reviewed: May 7th 2019Published: October 2nd 2019

DOI: 10.5772/intechopen.86709

Downloaded: 808

1. Introduction

Skeletal muscle tissue accounts for almost half of the human body mass. Human health is markedly affected by any deterioration in the material, metabolic, and contractile properties of skeletal muscle. Skeletal muscle is a highly plastic organ that is modulated by various pathways controlling cell and protein turnover.

Loss of muscle is a serious consequence of many chronic diseases and of aging itself. Muscle loss is also common in muscular dystrophy, in which marked loss of various membranous structural proteins occurs around muscle fibers [1]. Defects in components of the dystrophin-glycoprotein complex (DGC) are known to be an important cause of different muscular dystrophy.

Nowadays, the autophagy-dependent system and ubiquitin-proteasome signaling (UPS) are well known as a major intracellular degradation system, and its appropriate function is crucial to health and muscle homeostasis. Indeed, muscle wasting and weakness such as cachexia, dystrophy, and sarcopenia is characterized by marked decreases in the protein content, muscle fiber size, and muscle strength. Interestingly, a functional defect in autophagy-dependent signaling in sarcopenic mice and humans was recently suggested [2, 3]. In addition, apparent defect of autophagy-dependent signaling is also observed in various muscular dystrophies. Indeed, De Palma et al. [4] have described marked defect of autophagy in dystrophin-deficient mdx mice and Duchenne muscular dystrophy (DMD) patients through the electron microscopic evaluation of muscle tissue and decreased autophagic regulator proteins (i.e., Bnip3, Atg12, and LC3-II). The adaptive changes of UPS are highly controversial in several muscular dystrophies such as DMD, LGMD, and Ullrich congenital muscular dystrophy [5], although UPS seems to not be activated in human sarcopenic muscle [6].


2. Various therapeutic approaches for muscle dystrophy

To attenuate various forms of muscular dystrophy, many researchers have investigated exercise-based, supplemental, pharmacological, and gene therapy approaches. Currently, there is no cure for patients suffering from muscular dystrophies. Although several researchers actively try to determine the effect of pharmacological inhibition of myostatin for DMD patients, it is heavily difficult to obtain positive effects and there are few possibilities for clinical application. Indeed, a randomized clinical trial of anti-myostatin for DMD patients had a trend toward improved muscle mass and performance, but was stopped early due to non-muscle side effects (i.e., epistaxis and telangiectasias) [7]. Glucocorticoids (GCs) are commonly used and still serve as a gold standard therapy, acting as anti-inflammatory drugs [8]. More recently, weekly, intermittent GCs treatment has been shown to provide a better alternative to a daily regimen without eliciting muscle atrophy [9]. Recently, more attention is paid to induced pluripotent stem cells (iPSCs) technology and their potential application in DMD treatment [10], although almost all studies used DMD model mdx mice. In addition, the strategy using CRISPR/Cas9 technology progressed dramatically for the restoration of functional dystrophin [11]. Young et al. [12] have found that removal of exons 45–55 resulted in the expression of the stable dystrophin protein in both cardiomyocytes and skeletal myotube in vitro. An increasing number of studies report successful and beneficial effects of CRISPR/Cas9 only animal models of muscular dystrophy. Thus, it seems to be necessary for substantial time for genome editing tools to apply the dystrophic patients.

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Kunihiro Sakuma (October 2nd 2019). Introductory Chapter: Muscular Dystrophy and Recent Therapeutic Strategy, Muscular Dystrophies, Kunihiro Sakuma, IntechOpen, DOI: 10.5772/intechopen.86709. Available from:

chapter statistics

808total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Clinical and Molecular Diagnosis in Muscular Dystrophies

By Gisela Gaina, Magdalena Budisteanu, Emilia Manole and Elena Ionica

Related Book

First chapter

Introductory Chapter: Current Status of Research Field in Muscle Tissue

By Kunihiro Sakuma

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us